--- title: "Takeda Pharmaceutical (NYSE:TAK) General Counsel Natalie Anne Marie Furney Sells 30,868 Shares of Stock" type: "News" locale: "en" url: "https://longbridge.com/en/news/295785108.md" description: "Takeda Pharmaceutical General Counsel Natalie Anne Marie Furney sold 30,868 shares valued at $527,842.80 on August 10 to cover tax withholding obligations from vested equity awards. This transaction reduced her ownership by 13.13%, leaving her with 204,298 shares. The sale was disclosed via an SEC filing." datetime: "2026-08-13T10:53:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295785108.md) - [en](https://longbridge.com/en/news/295785108.md) - [zh-HK](https://longbridge.com/zh-HK/news/295785108.md) generator: "portal-rs" --- # Takeda Pharmaceutical (NYSE:TAK) General Counsel Natalie Anne Marie Furney Sells 30,868 Shares of Stock ## Key Points - **Takeda CEO Julie So-Young Kim sold 89,090 shares** at an average price of $17.10, worth approximately $1.52 million. The sale covered tax-withholding obligations from vested equity awards, and she retained 391,489 shares. - Several other senior insiders also reduced their holdings, which could weigh on investor sentiment, although the transactions were reportedly tied to tax obligations rather than discretionary selling. - Takeda shares opened at $17.42, with a market capitalization of about $55.82 billion. Analysts collectively rate the stock **“Hold,”** with two Buy, one Hold and one Sell rating. Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) General Counsel Natalie Anne Marie Furney sold 30,868 shares of Takeda Pharmaceutical stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $17.10, for a total transaction of $527,842.80. Following the sale, the general counsel directly owned 204,298 shares in the company, valued at $3,493,495.80. The trade was a 13.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. ## Takeda Pharmaceutical Price Performance - Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut Shares of NYSE TAK opened at $17.42 on Thursday. Takeda Pharmaceutical Co. has a 1 year low of $12.99 and a 1 year high of $18.90. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62. The company's 50-day moving average is $16.49 and its 200 day moving average is $17.13. The stock has a market capitalization of $55.82 billion, a P/E ratio of 51.24 and a beta of -0.08. * * * * * * Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. The business had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. On average, sell-side analysts expect that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current year. ## Key Stories Impacting Takeda Pharmaceutical - Time to buy these 3 healthcare companies that raised revenue guidance? Here are the key news stories impacting Takeda Pharmaceutical this week: - Neutral Sentiment: The sales were explicitly made to cover tax-withholding obligations tied to the vesting of equity awards, rather than representing discretionary open-market selling. Each insider retained a substantial stake after the transactions, reducing the concern that management is broadly abandoning the company. SEC insider filing - Negative Sentiment: The volume and seniority of the sellers could weigh on investor sentiment. CEO Julie So-Young Kim sold 89,090 shares, while Andrew Stewart Plump sold 165,393 shares. General Counsel Natalie Anne Marie Furney, Giles Richard Platford, Lauren Rusckowski Duprey and several other insiders also reduced their holdings, with individual ownership declines ranging from about 6.6% to 18.5%. SEC insider filing ## Analyst Upgrades and Downgrades A number of research firms have recently commented on TAK. Weiss Ratings cut Takeda Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Thursday, July 30th. Wall Street Zen raised Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a research note on Saturday, July 18th. Finally, Zacks Research upgraded Takeda Pharmaceutical from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 4th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold". - Price Growth & Yield: For That Magical Combo, Leave the U.S. **View Our Latest Stock Analysis on Takeda Pharmaceutical** ## Institutional Investors Weigh In On Takeda Pharmaceutical A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Private Trust Co. NA increased its stake in shares of Takeda Pharmaceutical by 84.7% during the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company's stock valued at $27,000 after purchasing an additional 783 shares in the last quarter. Parkside Financial Bank & Trust lifted its holdings in shares of Takeda Pharmaceutical by 192.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company's stock valued at $40,000 after purchasing an additional 1,684 shares during the last quarter. SHP Wealth Management bought a new stake in shares of Takeda Pharmaceutical in the 4th quarter worth approximately $42,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Takeda Pharmaceutical by 313.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company's stock worth $48,000 after purchasing an additional 2,328 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its stake in shares of Takeda Pharmaceutical by 56.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company's stock worth $55,000 after buying an additional 1,292 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company's stock. ## Takeda Pharmaceutical Company Profile (Get Free Report) Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas. Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations. ## Read More - Five stocks we like better than Takeda Pharmaceutical - GE Vernova’s AI Power Boom Faces a Profit Test - Cardinal Health Earnings: Can Perfection Get Priced In Twice? - Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand - Legacy Jet Builders Stall While Embraer Accelerates to New Highs *This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to \[email protected\].* Insider Buying or Selling at Takeda Pharmaceutical? Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Takeda Pharmaceutical and related companies. From Our Partners ALERT: Drop these 5 stocks before the market opens tomorrow! The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc... Weiss Ratings Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top... InvestorPlace Ready to give options a try? Your first trade (Ticker included) -INSIDE Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st... Base Camp Trading They didn't warn anyone in 1971. This time someone is warning you. On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb... Reagan Gold Group Buy this stock today Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo... Chaikin Analytics CODE RED: AI Meltdown Imminent? After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri... Paradigm Press My top 3 AI picks for the next decade Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A... The Oxford Club Here’s the stock symbol I’ve promised Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b... Stansberry Research ### Related Stocks - [TAK.US](https://longbridge.com/en/quote/TAK.US.md) - [4502.JP](https://longbridge.com/en/quote/4502.JP.md) - [WVE.US](https://longbridge.com/en/quote/WVE.US.md) ## Related News & Research - [Takeda CHRO Nicola D. Greenway sells 12,980 ADS for $235,173.42](https://longbridge.com/en/news/296395853.md) - [Takeda Pharmaceutical Insiders Sold Shares Worth Over $3.5M](https://longbridge.com/en/news/295731657.md) - [Takeda Insiders Sold Shares Worth Over $3.2M](https://longbridge.com/en/news/295729897.md) - [Should FDA Approval of ORZEYFUL for Narcolepsy Type 1 Prompt Action From Takeda Pharmaceutical (TSE:4502) Investors?](https://longbridge.com/en/news/295300131.md) - [BUZZ-Tax and consulting firm Andersen rebounds after $189 mln secondary offering](https://longbridge.com/en/news/296503835.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**